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nancies. This is basedMelanoma is considered one of the immunogenic – if not the most immunogenic – malig-
on several observations.1. Spontaneous remissions occur occasionally.
2. In about 5% of melanomas no primary tumour is found. The genetic aberrations of these
tumours closely resemble those of cutaneous melanomas, and therefore are suggestive
of spontaneous regressions of the primary tumours.
3. Both primary tumours and metastases often have brisk lymphocytic infiltrates, a phe-
nomenon that is correlated with better outcome.
4. Studies of isolates of these tumour-infiltrating T lymphocytes have revealed that a pro-
portion of these cells recognise melanoma antigens.
5. Melanomas respond to immunotherapy.
These observations have led to over 30 years of research on immunotherapy for melanoma;
many of these efforts have failed, with only a few exceptions: interleukin-2 (IL-2) and to a
lesser degree interferon-a (IFN-h). Recently, new developments in immunotherapy have rev-
olutionised this treatment modality. Anti-CTLA4 has received approval from the Food and
Drugs Administration (FDA) and the European Medicines Agency (EMA) for the treatment of
stage IV melanomas based on the improvement in overall survival in phase III trials, and
more recently blockade of PD1/PDL1 interactions has shown objective clinical responses
in a stage IV melanoma in early-phase clinical trials. In addition, several independent sin-
gle-institution phase I/II trials using adoptive cell therapy have shown a consistently high
response rate, including durable complete remissions in a substantial percentage of treated
patients.
Now, for the first time, immunotherapy has moved beyond the treatment of melanoma as
both CTLA4 and PD1 blockade have been shown to induce objective responses in other
tumour types as well.
This chapter will discuss the mechanism of action, clinical efficacy and side effects of IL-2,
the novel treatments consisting of the immune checkpoint blockade drugs anti-CTLA4 and
anti-PD1 and adoptive cell therapy.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.1. Introduction
Of all treatments for malignancies, immunotherapy has been
the most extensively studied in metastatic melanoma. These
often experimental, immunotherapeutic interventions can be
divided into: (1) biologicals such as cytokines, including inter-
leukin-2 (IL-2), interferons and granulocyte–monocyte colony-
stimulating factor (GM-CSF); (2) vaccination strategies such aspeptide vaccines, whole-protein vaccines, virus-based vac-
cines, DNA vaccines and dendritic-cell-based vaccines; (3)
adoptive cell therapy with lymphokine-activated killer cells
(LAKs), tumour-infiltrating lymphocytes (TILs), peripheral-
blood-derived melanoma-specific T cells and gene-modified
T-lymphocytes and (4) immune checkpoint inhibitors, includ-
ing anti-CTLA4, anti-PD1 and anti-PDL1 and immune co-
stimulatory molecules, including anti-CD137. These
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not only primary melanomas – especially primary superficial
spreading skin melanomas, but also metastatic disease – can
spontaneously regress [1]. In addition, about 5% of patients
present with melanoma metastases, often lymph-node
metastases, and sometimes also visceral metastases, without
any sign of primary melanoma on dermatological inspection.
Recently, it was shown that the genetic make-up (BRAF and
NRAS mutations) of these unknown primary melanomas is
very similar to that from non-chronic sun-damaged
(non-CSD) skin melanomas, suggesting that the primary
melanomas may have spontaneously regressed [2].
Little is known about the exact frequency of spontaneous
regressions in melanoma, but it is considered to be low
(around 3%), although some reviews have mentioned fre-
quencies above 15%. In a review from 2009, describing 76
cases from 1866 and onwards, the proposed mechanisms
for spontaneous regressions are thought to involve immune,
endocrine, inflammatory and tumour environmental nutri-
tional factors [3]. Although all of the above are probably in-
volved, the focus of this review is on immune factors.
The role of lymphocytic infiltrates in melanoma was first
described by Clemente et al., showing that brisk infiltration
by tumour-infiltrating lymphocytes (TILs) into primary mela-
nomas was correlated with better survival [4,5]. Later this was
also shown for TILs in metastatic lesions [6], suggesting a cau-
sal role for TILs in tumour control. In addition, in the past
20 years many tumour antigens have been discovered that
we now know are recognised by TILs. T cells derived from TILs
were shown to recognise melanocyte differentiation antigens
gp100, tyrosinase and MART-1/Melan-A. Other genes were
discovered in the 1990s, such as melanoma-associated genes
(MAGE) and NY-eso-1 [7–16]. In contrast to proteins that be-
long to the melanocyte differentiation antigens, these gene
products are derived from aberrantly expressed genes by tu-
mours, which play a physiological role during foetal develop-
ment, are silenced thereafter, but are still present mainly in
the testis. Thus, these genes have been named cancer/testis
genes. Very recently, it was demonstrated that TILs can also
recognise mutated antigens (van Rooij et al., J Clin Oncol, in
press). Melanoma has the highest frequency of mutations of
all cancers [17,18]. The vast majority of these mutations carry
a typical ultraviolet light signature. Using next-generation
DNA sequencing and RNA sequencing of tumours from paired
tumour and TIL samples, many mutations that potentially
carried a new T-cell epitope were found. Using major histo-
compatibility complex (MHC) tetramers, TILs from these tu-
mours were screened for the presence of T cells specific for
these mutated or neo-antigens. Within four tumour–TIL
pairs, four mutated antigen-specific T-cell populations could
be detected, some at high frequencies.
On the basis of these studies and clinical responses ob-
served in patients treated with immunotherapy, melanoma
can be considered one of the immunogenic types of cancer
– perhaps even the most immunogenic cancer.
In the past 30 years many trials focusing on immunother-
apy have been performed: in the early days with cytokines,
combinations of chemotherapy and cytokines, peptide vac-
cine trials, other vaccine trials (including DNA vaccines, viral
vaccines, whole-protein vaccines, tumour-cell vaccines anddendritic-cell vaccines) and adoptive cell therapy with LAK
cells, melanoma-specific T-cell clones or peripheral-blood-de-
rived melanoma-specific T cells. With the exception of high-
dose IL-2, many trials failed, including the combination of
chemotherapy and cytokines, the LAK cell therapy and many
vaccine trials. Others showed responses in a minority of pa-
tients, some of which were very durable, but many strategies
were not taken to phase III trial level because of lack of activ-
ity. In the past decade, immunotherapy has become much
more successful, and ipilimumab is the first therapy to show
an improvement in overall survival (OS). It is likely that also
new developments such as anti-PD1/PDL1 will change the
survival of patients. Adoptive cell therapy has become a po-
tent therapy and will hopefully be investigated in randomised
controlled trials (RCTs) as well. This review focuses on the
therapies that have impacted on the lives of stage IV mela-
noma patients.2. Clinical immunotherapy of metastatic
melanoma
2.1. Immunotherapy by infusional high-dose IL-2 boluses
High-dose interleukin-2 was tested in murine models of sar-
coma and melanoma and shown to lead to regression of
established transplantable pulmonary metastases and
subcutaneous tumours. The idea was that infusion of
high-dose IL-2 led to the activation of lymphocytes, generat-
ing lymphokine-activated killer cells in vivo, since infusion
of in vitro activated lymphocytes was highly active in murine
tumour models. In 1985, based on the observations in
mouse models, the first patients with metastatic cancer
(mostly melanoma) were treated with purified IL-2, given
as bolus infusions intravenously (i.v.) every 8 h. In some pa-
tients with melanoma objective partial clinical responses
were seen [19]. Toxicity in these patients consisted of fever,
chills and gastrointestinal tract symptoms such as nausea
and diarrhoea, hypotension, severe weight gain, anaemia,
leucocytopaenia and thrombocytopenia [20]. In Europe,
studies with continuous high-dose IL-2 i.v. infusion led to
even more toxicity; many patients required admission to
the intensive care unit (ICU) and some patients succumbed
to this treatment. In many studies, especially in patients
with either metastatic melanoma or metastatic renal cell
carcinoma, lower doses of IL-2 have been tested. Although
clinical responses were observed in a minority of patients,
the durability of these responses has been short. On the ba-
sis of consistent achievement of durable complete remis-
sions in 5–10% of patients with high-dose bolus IL-2
infusions in phase II trials, this treatment was Food and
Drugs Administration (FDA)-approved for the treatment of
metastatic melanoma in 1998, because of an unmet need
in this patient population [21]. High-dose IL-2 still is one
of the treatment options for stage IV melanoma (and for
metastatic renal-cell carcinoma) in the United States (US).
In particular, patients with good performance status and
M1a or M1b disease may benefit from this treatment. In Eur-
ope, high-dose IL-2 for these indications has not been ap-
proved and is therefore hardly used.
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720,000 IU/kg as an i.v. bolus (15 min infusion), every 8 h for
no more than 15 boluses, followed by about 10 days of rest,
followed by another 15 infusions. This is considered one
course. Patients are followed every 2–4 months for prolonged
periods of time.
The exact mechanism of action of high-dose IL-2, despite
its presence in the clinic for over 20 years, remains elusive.
IL-2, discovered as a T-cell growth factor in 1976 [22], is a
133-amino-acid protein which binds to the IL-2 receptor (IL-
2R) present on T cells, B cells and NK cells. The IL-2R can con-
sist of two or three chains, the IL2Ra, IL-2Rb and IL-2Rc
chains. The IL-2Ra and b chains form the low-affinity IL-2R
and all three chains form the high-affinity IL-2R. Both recep-
tors can deliver signals upon binding IL-2. Since the IL-2R is
widely expressed on cells from the adaptive immune system,
the presence of IL-2R (on subpopulations of cells) is not a pre-
dictive biomarker for response to treatment. In fact, so far no
biomarker of response has been found for high-dose IL-2
treatment. Recently, in a retrospective study, a non-statisti-
cally greater objective response rate was found for patients
with melanomas harbouring an NRAS mutation (compared
to BRAF mutation or wild-type tumours) [23]. Wang et al.
studied the molecular patterns associated with response to
treatment and observed that high-dose IL-2 has immense im-
pact on gene profiles of peripheral-blood mononuclear cells
(PBMCs), while the molecular changes within the tumours
were small and differed between lesions [24]. Analyses of
transcriptional profiles pre- and post-treatment with high-
dose IL-2 in PBMCs did not reveal a statistically significant sig-
nature. Interestingly, within the same tumours analyses on
pre- and post-fine-needle aspirates did not show important
changes within genetic profiles; however, an immune re-
sponse signature present pre-treatment was associated with
better prognosis: complete remission (CR), partial remission
(PR) and stable disease SD versus progressive disease PD.
These results suggest that response to immune therapy with
IL-2 is predetermined and can be measured by the presence of
an immune response genetic signature within the tumour.
However, the study was small, and validation in a larger study
is warranted before gene profiling can be used to select pa-
tients for high-dose IL-2 treatment.
Clinical biomarkers that are associated with response re-
sult from pooled retrospective analyses of metastatic mela-
noma patients treated with high-dose IL-2 in several trials.
Durable responses were almost only observed in patients with
Eastern Cooperative Oncology Group (ECOG) 0–1 performance
status and pulmonary, lymph-node and subcutaneous metas-
tases (M1a and M1b) [25].
Despite the lack of knowledge on the mechanism of action
of high-dose IL-2, this treatment remains one of few that
gives rise to durable CRs. Probably a large proportion of these
CRs are cured from melanoma [26].
In the past years, IL-2 has been combined with other ther-
apies. These combined modalities consisted of IL-2 with or
without gp100 peptide vaccination [27], IL-2 combined with
stereotactic radiotherapy (RT) [28], IL-2 combined with anti-
CTLA4 antibody ipilimumab [29] and IL-2 combined with infu-
sion of ex vivo expanded tumour-infiltrating lymphocytes [30].
The only randomised controlled study was performed by Sch-wartzentruber et al., which illustrated an improved response
rate and progression-free survival for the combined modality
arm consisting of gp100 peptide vaccine + high-dose IL-2
compared with high-dose IL-2 alone [27]. Combinations of
stereotactic RT and IL-2 or ipilimumab and IL-2 were tested
in small single-arm phase I/II studies [28,29]. Both combina-
tions showed an unexpectedly high response rate, including
complete remissions.
Taken together, high-dose IL-2 has been the oldest ap-
proved form of immunotherapy for metastatic melanoma.
Despite the development of new immunotherapies, high-
dose IL-2 remains a valid treatment option, especially in the
US.
2.2. Immunotherapy by immune checkpoint blockade
For T-cell activation a dual signalling step is required. The first
essential step is binding of the T-cell receptor to its cognate
antigen, the major histocompatibility complex (MHC) peptide
complex presented by antigen-presenting cells (APCs). The
second step is binding of the co-stimulatory molecule CD28
to CD80/CD86 (B7.1/B7.2) on the APC. The combined signalling
leads to full T-cell activation, resulting in up-regulation of IL-2
and IL-2R gene expression and cell division. Next to CD28, T
cells also express cytotoxic T-lymphocyte antigen-4 (CTLA4),
a co-inhibitory molecule, which binds the same ligands as
CD28 but with higher affinity [31,32]. Due to differences in
both spatial and timely expression of CD28 and CTLA4, CTLA4
will appear at the cell surface later during the immune re-
sponse and will then out-compete CD28 signalling [33]. Sig-
nalling through CTLA4 will stop IL-2 and IL-2R gene
transcription and cell proliferation. Its key role as a regulator
of immune responses was well established in CTLA4-deficient
mice that, upon exposure to environmental antigens after
birth, develop a severe and lethal lymphoproliferative disease
due to uncontrolled and persistent T-cell activation, prolifera-
tion and infiltration in peripheral tissues [34]. Blockade of
CTLA4 signalling by monoclonal antibodies has demonstrated
anti-tumour activity in murine models. In the case of immu-
nogenic tumours, single-agent CTLA4 blockade was enough
to induce tumour shrinkage, whereas in other models anti-
CTLA4 synergised with other treatment modalities to induce
efficacious antitumour immune responses (reviewed in [35]).
In the B16 melanoma model, the combination of vaccination
with irradiated GM-CSF gene transduced tumour cells and
CTLA4 blockade was successful in eradicating the tumour
[36]. These animals developed autoimmune depigmentation
or vitiligo, which was dependent on CD8 T cells, indicating
breaking of immune tolerance in these animals. CTLA4 is ex-
pressed not only by CD8 T cells, but also by CD4 T cells and
even high by CD4 FoxP3 regulatory T cells. Whether anti-
CTLA4 works through the blockade of CTLA4 on CD4 and
CD8 T cells, or through another mechanism involving regula-
tory T cells, has still not been revealed [37].
Two fully human monoclonal antibodies were developed
for use in humans, ipilimumab (MDX-010) and tremelimumab
(CP-675,206). Ipilimumab was the first monoclonal antibody to
be tested in patients with metastatic melanoma [38]. In these
early studies, which enrolled only a few patients, tumour
regressions and autoimmune adverse events were observed.
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phase I trial [39]. Comparable to ipilimumab, tremelimumab
also leads to tumour regression, and also to uncommon tox-
icities, including dermatitis, colitis, hepatitis and hypophysi-
tis, indicating that immunological tolerance was broken in
some patients treated with CTLA4 blockade. Originally, an
association between the incidence of immune-related ad-
verse events and clinical response were thought to be present
[40]; however, this could not be confirmed in the randomised
controlled trials that have been performed with these agents.
Ipilimumab was studied in two large randomised controlled
trials [41,42]. The first trial was a second-line study in stage
IV melanoma; 676 HLA-A*0201-positive patients were ran-
domised in a 3:1:1 ratio between the combination of ipi-
limumab and gp100 vaccine, ipilimumab (+ placebo) and
gp100 vaccine (and placebo). In this study ipilimumab was gi-
ven in a dose of 3 mg/kg every 3 weeks four times. The pri-
mary endpoint of the study was overall survival. With a
median follow-up of between 17 and 28 months, a statistically
significant difference in median survival was observed in
both ipilimumab arms (10.0 and 10.1 months) compared to
gp100 vaccine alone (6.4 months). The objective response rate
for ipilimumab plus vaccine was 5.7% and for ipilimumab
alone 10.9% compared with 1.5% for the gp100 vaccine group.
At 1 year 43.6% and 45.6% of patients in the ipilimumab arms
and 25.3% in the vaccine arm were alive, also at 2 years 21.6%,
23.5% and 13.7% respectively. Grade 3–4 immune-related ad-
verse events were experienced by 10–15% of the patients,
and seven deaths (1%) were associated with immune-related
side effects. Although preclinical data and an early clinical
trial suggested synergy between gp100 vaccine and CTLA4
blockade [38], this could not be confirmed in this large RCT.
Based on the statistically significant improvement in overall
survival, ipilimumab was approved as first- (US) or second-
line (European Union (EU)) treatment for patients with stage
IV melanoma. In the second phase III trial ipilimumab com-
bined with dacarbazine was compared with dacarbazine
alone. Here ipilimumab was given in a dose of 10 mg/kg every
3 weeks four times, followed by maintenance every 3 months.
Comparably to the second-line ipilimumab trial, this trial also
found a statistically significant improvement in overall sur-
vival in the patients treated with ipilimumab plus DTIC
(11.2 months) compared with DTIC plus placebo (9.1 months).
At 3 years, 20.8% of patients in the ipilimumab arm were still
alive compared with 12.2% in the DTIC alone arm. In 56.3% of
patients grade 3–4 adverse events were observed. Whereas in
the MDX-010-20 trial gastrointestinal adverse events were
most frequent, only 36% of patients received in the second
trial all four doses of ipilimumab treatment, mostly because
of liver toxicity. This unexpected observation of hepatotoxic-
ity was attributed to the combination of DTIC plus
ipilimumab. Hence, the combination of DTIC plus ipilimumab
is not recommended.
Tremelimumab was tested in a classical phase I design and
the recommended dose for phase II studies was 15 mg/kg
every 3 months [43]. Subsequently tremelimumab was stud-
ied in a randomised controlled phase III trial in stage IV mel-
anoma patients as first-line therapy compared with
dacarbazine [44]. Although a trend towards improved overall
survival was seen in this study, this difference was not statis-tically significant. In part this may have been due to the fact
that patients with lactate dehydrogenase levels more than
twice the upper limit of normal were excluded from the study,
whereas these patients were included in the ipilimumab piv-
otal trials. Therefore, the survival in the control arm may
have been better and the difference in overall survival (OS) be-
tween the two arms smaller. In addition, at least 16% of pa-
tients in the dacarbazine arm were treated with ipilimumab
upon failure, which may also have contributed to a better
OS in the control arm. Patients with an objective response
to tremelimumab had a considerably longer duration of this
response (35.8 months) compared with patients responding
to dacarbazine (13.7 months).
Recently, in a series of 752 patients who were treated with
ipilimumab for stage IV melanoma, 120 adverse events were
described [45]. These adverse events ranged from drug reac-
tions – sometimes severe and accompanied with eosinophilia
and systemic symptoms (DRESS syndrome), small bowel per-
foration, ischaemic gastritis, hepatitis, pancreatitis, nephritis,
hypophysitis, aseptic meningitis, alveolitis and even cardiac
fibrosis. Others had already described rare conditions such
as Guillain–Barre´ syndrome and sarcoidosis [46,47]. Algo-
rithms have been developed to treat patients that develop ad-
verse events. Most patients will require immediate
corticosteroid therapy, and sometimes other immunosup-
pressive agents such as infliximab in the case of severe colitis
that does not respond promptly to high-dose steroid therapy,
and mycophenolate mofetil or even anti-thymocyte globulin
(ATG) in the case of fulminant hepatitis.
In summary, CTLA4 blockade is an aspecific immunother-
apeutic strategy which was the first therapy to show a statis-
tical significant improvement in median overall survival in
melanoma in two phase III trials. About 20–25% of patients
will experience durable, mostly partial remissions, some even
complete remissions. Ipilimumab is the only approved immu-
notherapeutic drug. Toxicity of ipilimumab occurs in about
50–70% of patients, with 10–20% being serious, mostly im-
mune-related adverse events. Preferably, ipilimumab should
be administered to patients by experienced clinicians. Ipi-
limumab has been approved for first- or second-line therapy
in the US and as second-line treatment in Europe. Patients
with absolute lymphocyte count >1 · 109/L or with an in-
crease in ALC at the second infusion are more likely to benefit
[48,49]. However, validated predictive biomarkers are still
lacking.
Next to CTLA4, programmed death-1 (PD1) protein is an-
other cell-surface molecule that has inhibitory properties
[48,49]. In contrast to CTLA4, PD1 expression is involved in
inhibition of T cells in peripheral tissues during inflammation
[37,50]. Upon activation, PD1 is expressed on CD4+ and CD8+ T
cells and B cells, which results in the inhibition of e.g. T-cell-
receptor- (TCR-)mediated signalling, probably through activa-
tion of phosphatase SHP2 [51]. The ligands of PD1 are PD-L1
(B7-H1) and PD-L2 (B7-CD) on APCs [52]. However, PD-L1
expression may also be induced on tumour cells [53,54]. Inter-
action between PD1-positive T cells and PD-L1-expressing
tumour cells was therefore suggested to hamper proper T-cell
function and appears to be one of the immunosuppressive
mechanisms executed by tumours to escape an initially ongo-
ing immune control [54,55]. Similarly to CTLA4 expression on
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CD4 T cells. Therefore the blockade of PD1 by anti-PD1 anti-
bodies may work through breaking the inhibitory interaction
between PD1+ CD4 and CD8 T cells and PD-L1-expressing
tumour cells, or by decreasing the number or function of reg-
ulatory T cells. Similarly, antibodies specific for PD-L1 can re-
store the function of tumour-specific PD1+ CD4 and CD8 T
cells.
Both anti-PD1 and anti-PD-L1 antibodies are now in clini-
cal trials. Nivolumab (MDX-1106; BMS 936558; ONO-4538)
was the first anti-PD1 antibody to be tested in a phase I study
(n = 39) as a single agent in several tumour types, including
melanoma, renal cell carcinoma and non-small-cell lung can-
cer (NSCLC) [56]. Based on its mechanism of action, similar
toxicity as had been seen in anti-CTLA4 treatment was ex-
pected; however, anti-PD1 – given in doses ranging from 0.3
to 1, 3 and 10 mg/kg – was quite safe. After one dose no
dose-limiting toxicity was observed. Grade 3 toxicity con-
sisted of CD4 lymphopaenia, fatigue and musculoskeletal
problems. As far as immune-related adverse events were con-
cerned, one patient developed colitis and one patient hypo-
thyroidism. The first responded to corticosteroids and
infliximab, the other was treated by thyroid hormone replace-
ment. Since anti-PD1 treatment was well tolerated, the max-
imum tolerated dose (MTD) could not be determined from
this study.
Recently, the results from the extension phase of this
phase I study – involving 296 patients with either melanoma,
renal-cell carcinoma (RCC) or NSCLC – were published [57].
Objective response rate in melanoma was 28%, and the
majority of these responses were durable, lasting longer than
1 year. Interestingly, the authors found a strong correlation
between cell-surface expression of PD-L1 on tumour cells
and response to anti-PD1 treatment. So far an objective re-
sponse was observed in none of the patients lacking tumour
PD-L1 expression, indicating that PD-L1 expression may be
an important predictive biomarker for treatment with anti-
PD1.
Brahmer et al. published the results from a phase I study
with anti-PD-L1 (MDX-1105) [58]. In total, 207 patients were
treated, of whom 52 had metastatic melanoma; 17% of the
melanoma patients developed an objective response. Only a
minority of patients developed grade 3–4 toxicity (9%). Im-
mune-related adverse events were also observed during this
study, but were manageable. Also for anti-PD-L1 the MTD
could not be defined. Apart from MDX-1105 and MDX-1106,
several other antibodies are currently in development: CT-
011 and MK-3475 are both anti-PD1 antibodies, RG7446 and
MEDI4736 are anti-PD-L1 antibodies, while MP-224 is an Fc-
fused PD-L2, a molecule that inhibits PD-1 signalling.
In summary, blockade of PD1/PD-L1 interaction at the tu-
mour site by inhibitory antibodies appears to be another
promising immunotherapeutic strategy for the treatment of
melanoma. These drugs seem less toxic than anti-CTLA4
and appear to induce a higher objective response rate, of
which a large proportion appears to be durable. Large ran-
domised controlled trials with these drugs are ongoing. So
far, on the basis of extended phase I trial results, the toxicity
profile of anti-PD1 appears to be better compared with ipi-
limumab. In addition, the response rate of anti-PD1 appearsto be higher in patients with metastatic melanoma. Random-
ised controlled trials comparing ipilimumab directly with
anti-PD1 or the combination of ipilimumab and anti-PD1 are
ongoing and should reveal which patients will benefit most
from anti-PD1 treatment and when.3. Immunotherapy by adoptive cell therapy
3.1. Tumour-infiltrating lymphocytes (TILs)
In the 1980s, adoptive cell therapy was tested in clinical trials
based on the observation in murine models that infusion of
in vitro IL-2-activated lymphocytes was highly effective in
the eradication of tumours. The infusion of these so-called
lymphokine-activated killer (LAK) cells in melanoma patients
was compared with high-dose IL-2 alone and was not shown
to be statistically significantly superior in response rate, pro-
gression-free survival or other outcomes of the trial [59]. It
took until early 2000 before the infusion of T cells led to
impressive response rates in substantial numbers of patients
with metastatic melanoma. Dr. S. Rosenberg and colleagues
showed that infusion of in vitro cultured TILs derived from a
large melanoma metastasis was able to induce regression of
bulky metastatic disease and even complete remissions in
some patients [30,60]. From previous experiments and mouse
models, it became apparent that prior depletion of host lym-
phocytes greatly improved the in vivo survival of the infused
TILs, and a short in vitro culture time was important for sur-
vival, in vivo expansion and efficacy. Based on these observa-
tions, heavily pre-treated metastatic melanoma patients were
treated with lympho-depleting chemotherapy, consisting of
high-dose cyclophosphamide and fludarabin, followed by
infusion of large numbers of TILs (around 1 · 1011 cells) fol-
lowed by bolus infusion of high-dose IL-2 (up to 15 boluses)
[30,60]. This conditioning regimen results in short but deep
leukopaenia, including neutropenia and lymphopaenia, but
is non-myeloablative and thus does not require peripheral
haematopoietic stem cell (HSC) support. Mouse models
showed that depletion of the lymphocytic compartment not
only results in the creation of physical space for the infused
TILs, but also results in much less competition from host lym-
phocytes for the homeostatic cytokines IL-7 and IL-15, giving
a head start to the infused cells [61]. Secondly, lympho-deple-
tion also diminishes the immunosuppressive cell popula-
tions, such as regulatory T cells from the circulation. Based
on the results from the first trial, in later studies lympho-
depleting regimens were intensified to combination of che-
motherapy with total body irradiation (TBI) up to 12 Gy [62].
Naturally, this heavy conditioning regimen necessitated
bone-marrow rescue by HSC support. In small phase I/II stud-
ies each with 25 patients, escalation of TBI combined with
cyclophosphamide plus fludarabin resulted in further
improvement in response rates to up to 72%, with 10–20% of
patients acquiring a durable complete response. Not surpris-
ingly, the treatment was harsher on the patients, resulting
in more acute adverse events and prolonged organ dysfunc-
tion [62]. In the early studies cultured TILs were selected for
reactivity against autologous melanoma cell lines, and if not
present HLA-matched allogeneic melanoma cell lines. The
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since the final dose of infused T cells was around 1 · 1011 cells.
In subsequent studies, this selection step was deleted from
the protocol, which simplified the production process sub-
stantially. Importantly, this did not harm the objective re-
sponse rate, which remained around or above 50%,
including the occurrence of complete responses [63]. The sim-
plified protocol of non-selected TILs was subsequently
adopted by several laboratories in the US and in Israel [64–
66]. By now several studies using this protocol, but without
the addition of TBI to the non-myeloablative chemotherapy
regimen, have shown a highly consistent objective response
rate of 40–50% of treated patients. In order to widely distribute
TIL treatment over Europe, a randomised controlled trial is
required.
3.2. Gene-modified T cells
Because TIL therapy is not always feasible, and because of the
complexity of the treatment, alternatives for adoptive cell
therapy with TILs have been developed. One of the most
promising new strategies is the use of tumour-specific anti-
gen receptors [67]. These tumour-specific receptors can be de-
rived from a tumour-specific T-cell clone with a high-affinity
T-cell receptor (TCR) that recognises a human MHC/tumour-
derived peptide complex, or from a high-affinity antibody
specific for a cell-surface tumour antigen. These antibody-
based receptors, called chimeric antigen receptors (CARs),
are genetically fused to proteins of the T-cell receptor signal-
ling machinery (CD3f, CD28 and others), so that T lympho-
cytes genetically changed to express these receptors upon
antigen binding will be properly activated [68].
For the genetic transfer of TCR or CAR genes to T cells sev-
eral options exist; however, the most widely used is transfer
by retroviral infection. These retroviruses and lentiviruses
are genetically modified to contain the genes for a specific
CAR/TCR. In addition, these viruses have been crippled to pre-
vent replication. Upon infection of the T lymphocytes these
viruses place the genes encoding the CAR/TCR more or less
randomly into the host-cell genome. Thus, these receptors
can be genetically transferred into peripheral-blood T lym-
phocytes, thereby creating an army of tumour killer cells.
So far tumour-specific T-cell receptors have been used only
for diseases other than melanoma; for example, a high-affinity
CD19 binding antibody has been used successfully in B-cell
lymphomas/leukaemia [69–71].
For melanoma, patients have been treated with TCR-
transduced T cells specific for MART-1, NY-eso-1 and more re-
cently also for MAGE-A3 [72–75]. In all three trials, objective
responses have been observed. So far, gene therapy with the
NY-eso-1-specific TCR was most effective and safest. In the
trials with the MART-1-specific TCR, a substantial portion of
patients developed on-target toxicity due to T-cell attack on
MART-1-positive cells in the body, leading to severe dermatitis
and vitiligo, uveitis and hearing loss (Kogt–Koyanagi–Harada
disease). In most instances these side effects were transient
and responsive to topical corticosteroids.
Apart from on-target toxicity – which is more likely to oc-
cur for TCRs specific for over-expressed gene products or dif-
ferentiation antigens, as normal tissues often also expressthese antigens – off-target toxicity is another potential dan-
ger of this treatment. The most important reason for this
type of toxicity is cross-reactivity of the introduced TCR with
an unknown antigen. Since TCRs recognise MHC peptide
complexes, and since most individuals have six different
MHC class I alleles, the chance of a TCR having affinity for
one of these plus an unknown peptide is not just theoretical.
Choice of target and knowledge about tissue expression of
the antigen for which the TCR is specific is going to be
crucial.
Taken together, adoptive cell therapy is still at the level of
early clinical trials; however, the efficacy of this treatment is
promising, with establishment of durable remissions in some
patients. With more centres performing these trials, the expe-
rience with this complex therapy is rapidly increasing. There-
fore, this treatment should be taken to the next level:
randomised controlled trials.
4. Conclusion
In conclusion, immune therapy of melanoma is by 2013 an
established and expanding strategy that can induce durable
responses in advanced-stage melanoma patients, some of
whom may be cured for life. Immunotherapy, however, comes
with a price. New and unexpected toxicities may develop dur-
ing the course of the treatment or after cessation of treatment
and requires experience in order to properly manage these
therapies. In addition, these therapies are costly and some-
times highly complex (TIL and TCR/CAR gene therapy). There-
fore research focused on finding biomarkers that predict
response to treatment, such as PDL1 tumour expression for
response to anti-PD1, will be one of the most important chal-
lenges for the coming years.
Apart from immunotherapy as a novel treatment option for
patients with stage IV melanoma, targeted therapy has also re-
cently changed the outcome of these patients. Drugs such as
vemurafenib, dabrafenib and trametinib have been shown to
prolong survival of metastatic melanoma patients harbouring
the common BRAF V600 mutation. With all these new thera-
pies now available, studies on selecting the best patient popu-
lation for each therapy, and on the optimal sequence of
treatments, will be key to most effectively prolonging the lives
of metastatic melanoma patients, also on the use of these ther-
apies in the most cost-effective manner.Conflict of interest statement
None declared.R E F E R E N C E S[1] Bennett WH. Lancet 1899;1:3.
[2] Jakob JA, Bassett Jr RL, Ng CS, et al. NRAS mutation status is
an independent prognostic factor in metastatic melanoma.
Cancer 2012;118(16):4014–23.
[3] Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression
of metastases from melanoma: review of the literature.
Melanoma Res 2009;19(5):275–82.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 9 7 –1 0 5 103[4] Oble DA, Loewe R, Yu P, et al. Focus on TILs: prognostic
significance of tumor infiltrating lymphocytes in human
melanoma. Cancer Immun 2009;9:3.
[5] Clemente CG, Mihm Jr MC, Bufalino R, et al. Prognostic value
of tumor infiltrating lymphocytes in the vertical growth
phase of primary cutaneous melanoma. Cancer
1996;77(7):1303–10.
[6] Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and
immunohistologic characteristics of tumor-infiltrating
immune cells are associated with clinical outcome in
metastatic melanoma. Cancer Res 2012;72(5):1070–80.
[7] Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte
lineage-specific antigen gp100 is recognized by melanoma-
derived tumor-infiltrating lymphocytes. J Exp Med
1994;179(3):1005–9.
[8] Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene
codes for an antigen recognized by autologous cytolytic T
lymphocytes on HLA-A2 melanomas. J Exp Med
1993;178(2):489–95.
[9] Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric
identification of a naturally processed melanoma peptide
recognized by CD8+ cytotoxic T lymphocytes. J Exp Med
1995;181(1):363–8.
[10] Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human
gene MAGE-3 codes for an antigen recognized on a
melanoma by autologous cytolytic T lymphocytes. J Exp Med
1994;179(3):921–30.
[11] Huang LQ, Brasseur F, Serrano A, et al. Cytolytic T
lymphocytes recognize an antigen encoded by MAGE-A10 on
a human melanoma. J Immunol 1999;162(11):6849–54.
[12] Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral
and cellular immune response against cancer-testis antigen
NY-ESO-1: definition of human histocompatibility leukocyte
antigen (HLA)-A2-binding peptide epitopes. J Exp Med
1998;187(2):265–70.
[13] Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the
gene coding for a shared human melanoma antigen
recognized by autologous T cells infiltrating into tumor. Proc
Natl Acad Sci U S A 1994;91(9):3515–9.
[14] Kvistborg P, Shu CJ, Heemskerk B, et al. TIL therapy broadens
the tumor-reactive CD8(+) T cell compartment in melanoma
patients. Oncoimmunology 2012;1(4):409–18.
[15] Romero P, Gervois N, Schneider J, et al. Cytolytic T
lymphocyte recognition of the immunodominant HLA-
A*0201-restricted Melan-A/MART-1 antigenic peptide in
melanoma. J Immunol 1997;159(5):2366–74.
[16] Traversari C, van der Bruggen P, Luescher IF, et al. A
nonapeptide encoded by human gene MAGE-1 is recognized
on HLA-A1 by cytolytic T lymphocytes directed against tumor
antigen MZ2-E. J Exp Med 1992;176(5):1453–7.
[17] Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver
mutations in melanoma. Cell 2012;150(2):251–63.
[18] Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing
identifies recurrent somatic RAC1 mutations in melanoma.
Nat Genet 2012;44(9):1006–14.
[19] Rosenberg SA, Yang JC, White DE, et al. Durability of
complete responses in patients with metastatic cancer
treated with high-dose interleukin-2: identification of the
antigens mediating response. Ann Surg
1998;228(3):307–19.
[20] Kammula US, White DE, Rosenberg SA. Trends in the safety
of high dose bolus interleukin-2 administration in patients
with metastatic cancer. Cancer 1998;83(4):797–805.
[21] Atkins MB, Lotze MT, Dutcher JP, et al. High-dose
recombinant interleukin 2 therapy for patients with
metastatic melanoma: analysis of 270 patients treated
between 1985 and 1993. J Clin Oncol 1999;17(7):2105–16.[22] Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of
T lymphocytes from normal human bone marrows. Science
1976;193(4257):1007–8.
[23] Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS
mutations with clinical response to high-dose IL-2 in
patients with advanced melanoma. J Immunother
2012;35(1):66–72.
[24] Weiss GR, Grosh WW, Chianese-Bullock KA, et al. Molecular
insights on the peripheral and intratumoral effects of
systemic high-dose rIL-2 (aldesleukin) administration for the
treatment of metastatic melanoma. Clin Cancer Res
2011;17(23):7440–50.
[25] Lee DS, White DE, Hurst R, et al. Patterns of relapse and
response to retreatment in patients with metastatic
melanoma or renal cell carcinoma who responded to
interleukin-2-based immunotherapy. Cancer J Sci Am
1998;4(2):86–93.
[26] Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the
use of high-dose interleukin-2 in the treatment of 652 cancer
patients. Ann Surg 1989;210(4):474–84 [discussion 484–5].
[27] Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100
peptide vaccine and interleukin-2 in patients with advanced
melanoma. N Engl J Med 2011;364(22):2119–27.
[28] Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of
stereotactic body radiotherapy and interleukin-2 – tumor and
immunological responses. Sci Transl Med
2012;4(137):137ra74.
[29] Maker AV, Phan GQ, Attia P, et al. Tumor regression and
autoimmunity in patients treated with cytotoxic T
lymphocyte-associated antigen 4 blockade and interleukin 2:
a phase I/II study. Ann Surg Oncol 2005;12(12):1005–16.
[30] Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer
regression and autoimmunity in patients after clonal
repopulation with antitumor lymphocytes. Science
2002;298(5594):850–4.
[31] Brunet JF, Denizot F, Luciani MF, et al. A new member of the
immunoglobulin superfamily – CTLA-4. Nature
1987;328(6127):267–70.
[32] Pentcheva-Hoang T, Egen JG, Wojnoonski K, et al. B7-1 and
B7-2 selectively recruit CTLA-4 and CD28 to the
immunological synapse. Immunity 2004;21(3):401–13.
[33] Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms
of T-cell inhibition and application to cancer therapy.
Immunol Rev 2008;224:141–65.
[34] Waterhouse P, Penninger JM, Timms E, et al.
Lymphoproliferative disorders with early lethality in mice
deficient in Ctla-4. Science 1995;270(5238):985–8.
[35] Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor
models: an overview of preclinical and translational
research. Cancer Immun 2013;13:5.
[36] van Elsas A, Hurwitz AA, Allison JP. Combination
immunotherapy of B16 melanoma using anti-cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/
macrophage colony-stimulating factor (GM-CSF)-producing
vaccines induces rejection of subcutaneous and metastatic
tumors accompanied by autoimmune depigmentation. J Exp
Med 1999;190(3):355–66.
[37] Pardoll DM. The blockade of immune checkpoints in cancer
immunotherapy. Nat Rev Cancer 2012;12(4):252–64.
[38] Phan GQ, Yang JC, Sherry RM, et al. Cancer regression
and autoimmunity induced by cytotoxic T lymphocyte-
associated antigen 4 blockade in patients with
metastatic melanoma. Proc Natl Acad Sci U S A
2003;100(14):8372–7.
[39] Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor
activity in melanoma and anti-self responses in a phase I
trial with the anti-cytotoxic T lymphocyte-associated antigen
104 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 9 7 –1 0 54 monoclonal antibody CP-675,206. J Clin Oncol
2005;23(35):8968–77.
[40] Weber J, Thompson JA, Hamid O, et al. A randomized,
double-blind, placebo-controlled, phase II study comparing
the tolerability and efficacy of ipilimumab administered with
or without prophylactic budesonide in patients with
unresectable stage III or IV melanoma. Clin Cancer Res
2009;15(17):5591–8.
[41] Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival
with ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010;363(8):711–23.
[42] Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus
dacarbazine for previously untreated metastatic melanoma.
N Engl J Med 2011;364(26):2517–26.
[43] Ribas A, Chesney JA, Gordon MS, et al. Safety profile and
pharmacokinetic analyses of the anti-CTLA4 antibody
tremelimumab administered as a one hour infusion. J Transl
Med 2012;10:236.
[44] Ribas A, Kefford R, Marshall MA, et al. Phase III randomized
clinical trial comparing tremelimumab with standard-of-care
chemotherapy in patients with advanced melanoma. J Clin
Oncol 2013;31(5):616–22.
[45] Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor
control: an analysis of rare side effects of anti-CTLA-4
therapy in metastatic melanoma from the ipilimumab
network. PLoS One 2013;8(1):e53745.
[46] Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced
Guillain–Barre syndrome in a melanoma patient. Ann Oncol
2011;22(4):991–3.
[47] Vogel WV, Guislain A, Kvistborg P, et al. Ipilimumab-induced
sarcoidosis in a patient with metastatic melanoma
undergoing complete remission. J Clin Oncol
2012;30(2):e7–e10.
[48] Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody
therapy: immune monitoring during clinical development
of a novel immunotherapy. Semin Oncol 2010;37(5):
473–484.
[49] Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily
practice with ipilimumab for the treatment of patients with
metastatic melanoma: an early increase in lymphocyte and
eosinophil counts is associated with improved survival. Ann
Oncol 2013;24:1697–703.
[50] Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor
involved in peripheral tolerance. Trends Immunol
2001;22(5):265–8.
[51] Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2
associate with immunoreceptor tyrosine-based switch motif
of programmed death 1 upon primary human T cell
stimulation, but only receptor ligation prevents T cell
activation. J Immunol 2004;173(2):945–54.
[52] Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second
ligand for PD-1 and inhibits T cell activation. Nat Immunol
2001;2(3):261–8.
[53] Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on
tumor cells with PD-1 on tumor-specific T cells as a
mechanism of immune evasion: implications for tumor
immunotherapy. Cancer Immunol Immunother
2005;54(4):307–14.
[54] Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7–
H1 promotes T-cell apoptosis: a potential mechanism of
immune evasion. Nat Med 2002;8(8):793–800.
[55] Taube JM, Anders RA, Young GD, et al. Colocalization of
inflammatory response with B7–h1 expression in human
melanocytic lesions supports an adaptive resistance
mechanism of immune escape. Sci Transl Med
2012;4(127):127ra37.
[56] Brahmer JR, Drake CG, Wollner I, et al. Phase I study of
single-agent anti-programmed death-1 (MDX-1106) inrefractory solid tumors: safety, clinical activity,
pharmacodynamics, and immunologic correlates. J Clin
Oncol 2010;28(19):3167–75.
[57] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N Engl J
Med 2012;366(26):2443–54.
[58] Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of
anti-PD-L1 antibody in patients with advanced cancer. N Engl
J Med 2012;366(26):2455–65.
[59] Rosenberg SA, Lotze MT, Yang JC, et al. Prospective
randomized trial of high-dose interleukin-2 alone or in
conjunction with lymphokine-activated killer cells for the
treatment of patients with advanced cancer. J Natl Cancer
Inst 1993;85(8):622–32.
[60] Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell
transfer therapy following non-myeloablative but
lymphodepleting chemotherapy for the treatment of patients
with refractory metastatic melanoma. J Clin Oncol
2005;23(10):2346–57.
[61] Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of
homeostatic cytokine sinks by lymphodepletion
enhances the efficacy of adoptively transferred
tumor-specific CD8+ T cells. J Exp Med 2005;202(7):
907–912.
[62] Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for
patients with metastatic melanoma: evaluation of intensive
myeloablative chemoradiation preparative regimens. J Clin
Oncol 2008;26(32):5233–9.
[63] Dudley ME, Gross CA, Langhan MM, et al. CD8+ enriched
‘‘young’’ tumor infiltrating lymphocytes can mediate
regression of metastatic melanoma. Clin Cancer Res
2010;16(24):6122–31.
[64] Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical
responses in a phase II study using adoptive transfer of
short-term cultured tumor infiltration lymphocytes in
metastatic melanoma patients. Clin Cancer Res
2010;16(9):2646–55.
[65] Joseph RW, Peddareddigari VR, Liu P, et al. Impact of clinical
and pathologic features on tumor-infiltrating lymphocyte
expansion from surgically excised melanoma metastases
for adoptive T-cell therapy. Clin Cancer Res 2011;17(14):
4882–91.
[66] Pilon-Thomas S, Kuhn L, Ellwanger S, et al. Efficacy of
adoptive cell transfer of tumor-infiltrating lymphocytes after
lymphopenia induction for metastatic melanoma. J
Immunother 2012;35(8):615–20.
[67] Schumacher TN. T-cell-receptor gene therapy. Nat Rev
Immunol 2002;2(7):512–9.
[68] Gross G, Waks T, Eshhar Z. Expression of immunoglobulin–T-
cell receptor chimeric molecules as functional receptors with
antibody-type specificity. Proc Natl Acad Sci U S A
1989;86(24):10024–8.
[69] Brentjens RJ, Riviere I, Park JH, et al. Safety and
persistence of adoptively transferred autologous CD19-
targeted T cells in patients with relapsed or
chemotherapy refractory B-cell leukemias. Blood
2011;118(18):4817–28.
[70] Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen
receptor-modified t cells for acute lymphoid leukemia. N Engl
J Med 2013.
[71] Porter DL, Levine BL, Kalos M, et al. Chimeric antigen
receptor-modified T cells in chronic lymphoid leukemia. N
Engl J Med 2011;365(8):725–33.
[72] Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy
with human and mouse T-cell receptors mediates
cancer regression and targets normal tissues expressing
cognate antigen. Blood 2009;114(3):535–46.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 9 7 –1 0 5 105[73] Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer
regression and neurological toxicity following anti-MAGE-A3
TCR gene therapy. J Immunother 2013;36(2):133–51.
[74] Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer
regression in patients after transfer of genetically engineered
lymphocytes. Science 2006;314(5796):126–9.[75] Robbins PF, Morgan RA, Feldman SA, et al. Tumor
regression in patients with metastatic synovial cell
sarcoma and melanoma using genetically engineered
lymphocytes reactive with NY-ESO-1. J Clin Oncol
2011;29(7):917–24.
